Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Cure for hepatitis C

The use of peginterferon alone, or in combination with ribavirin, points to a cure for hepatitis C, the leading cause of cirrhosis, liver cancer and the need for liver transplant, a Virginia Commonwealth University researcher said today.

22 May 2007

Peregrine Pharmaceuticals to initiate new Bavituximab HCV trial

Peregrine Pharmaceuticals has announced it has filed a new clinical trial protocol with the FDA to study bavituximab in patients co-infected with HCV and the human immunodeficiency virus (HIV).

18 May 2007

New test for liver disease

A researcher at the Stanford University School of Medicine has helped confirm the reliability of a new test for liver disease that is ushering in the long-promised era of personalized medicine based on each individual's genetic makeup.

30 Apr 2007

Liver center leading record number of studies to tackle hepatitis C

While many research institutions are suffering from funding cuts, Drs. Bruce R. Bacon and Adrian M. Di Bisceglie are chugging away with their usual tenacity.

27 Apr 2007

Rabies kills three despite proven experimental treatment

According to the Centers for Disease Control and Prevention (CDC) in the United States an experimental rabies treatment that saved the life of a Wisconsin teenager in 2004 has failed to help other children infected with the deadly virus.

23 Apr 2007

Human Genome Sciences reports results of phase 2b trial of Albuferon

Human Genome Sciences has reported results at Week 12 following the completion of therapy (SVR12) in a Phase 2b clinical trial of Albuferon(R) (albinterferon alfa-2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are naive to interferon alpha-based treatment regimens.

16 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

Schering-Plough commits to chronic hepatitis C research

Schering-Plough has reaffirmed its commitment to advancing the science and treatment of chronic hepatitis C virus (HCV) infection with several key data presentations at the European Association for the Study of the Liver (EASL) 42nd annual meeting in Barcelona, Spain, April 11-15.

11 Apr 2007

Antipodean Pharma commences phase 2 trial in hepatitis C

Antipodean Pharmaceuticals has announced it has initiated a Phase 2 clinical trial of its lead compound MitoQ (mitoquinone) to investigate the drug's efficacy to reduce liver damage in patients with raised liver enzymes associated with the Hepatitis C virus (HCV).

5 Feb 2007

Liver damage can be reversed

Saint Louis University Liver Center scientists are presenting research today on a more effective way to treat hepatitis C patients who have been unresponsive to current drug therapies.

30 Oct 2006

Treatments used for SARS no benefit to victims

Researchers have found, following a systematic review of all studies done on the 2003 SARS epidemic, that none of the treatments used to treat patients appear to have worked.

13 Sep 2006

SARS: Systematic review of treatment effects

The SARS virus set alarm bells ringing across the world when it first appeared in 2002, but now a review of the effectiveness of the treatments used against it has found no evidence that any of them worked.

12 Sep 2006

Racial differences in hepatitis C viral responses

African American patients with hepatitis C (HCV) infections experience a lower response rate to the peginterferon alfa-2a and ribavirin combination treatment than Caucasian Americans, according to a study published in the August issue of Gastroenterology.

16 Aug 2006

Statins stop the replication of the hepatitis C virus

A new study shows that statins, which are typically used as anti-cholesterol medications, can inhibit the replication of the hepatitis C virus (HCV).

9 Jul 2006

Impact of obesity on treatment of chronic hepatitis C

According to a new study, obese patients chronically infected with the hepatitis C virus (HCV) and treated with combination drug therapy may have better outcomes if the underlying abnormalities caused by excessive fat tissue are corrected.

6 Jun 2006

Organ-recipients' deaths prompt call for suppliers of pet rodents to screen for lymphocytic choriomeningitis virus

A case involving seven transplant recipients killed by a rodent-borne virus that they apparently acquired from donated and infected human organs has prompted a recommendation that regulatory authorities require suppliers of pet rodents to screen their colonies for the virus.

1 Jun 2006

Largest U.S. hepatitis C trial yields treatment insights

Community-Based WIN-R Study Shows Significantly Better Outcomes with Weight-Based Dosing

24 May 2006

Cyclosporine suppresses hepatitis C virus and increases the chance of a sustained virological response after liver transplantation

Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.

5 Jan 2006

Limitation of combination therapy of Interferon and Ribavirin for older patients with chronic hepatitis C

A new Japanese study examining the effects of combination therapy on older patients with hepatitis C found more adverse effects necessitating discontinuation of treatment, lowering of dosages, and lower long-term benefits in this age group.

5 Jan 2006

Largest hepatitis-C U.S. study defines optimal therapy

Final results of the WIN-R trial,[1] the largest hepatitis C study conducted in U.S. patients, showed that weight-based REBETOL (ribavirin, USP) in combination therapy with PEG-INTRON (peginterferon alfa-2b) achieved significantly higher rates of sustained virologic response (SVR)[2] and lower rates of relapse compared to the combination therapy using a flat dose of ribavirin.

14 Nov 2005